DDInter1679 DDInter899
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Sitagliptin {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
Sitagliptin {u} (Compound) binds {v} (Gene) DPP4
Sitagliptin {u} (Compound) upregulates {v} (Gene) TSPAN8
Sitagliptin {u} (Compound) is included by {v} (Pharmacologic Class) Dipeptidyl Peptidase 4 Inhibitors
Sitagliptin {u} (Compound) downregulates {v} (Gene) CTSD
Sitagliptin {u} (Compound) causes {v} (Side Effect) Back pain
Sitagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Sitagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dulaglutide
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quetiapine
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Corticotropin
Sitagliptin (Compound) treats type 2 diabetes mellitus (Disease)
Sitagliptin (Compound) binds DPP4 (Gene)
Sitagliptin (Compound) upregulates TSPAN8 (Gene)
Sitagliptin (Compound) is included by Dipeptidyl Peptidase 4 Inhibitors (Pharmacologic Class)
Sitagliptin (Compound) downregulates CTSD (Gene)
Sitagliptin (Compound) causes Back pain (Side Effect)
Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin